While ALOX5 inhibition triggers marked apoptosis in human prostate cancer cells [138], it is overexpressed in prostate adenocarcinoma, PDAC [139], hepatocellular carcinoma [140], and high-grade astrocytomas [141]. This evidence concerns the gene ALOX5 and hepatocellular carcinoma.